Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




CtDNA Forecasts Non-Metastatic Colorectal Cancer Recurrence

By LabMedica International staff writers
Posted on 29 May 2019
Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). More...
Most colorectal cancers are due to old age and lifestyle factors, with only a small number of cases due to underlying genetic disorders.

Colorectal cancer diagnosis is performed by sampling of areas of the colon suspicious for possible tumor development, typically during colonoscopy or sigmoidoscopy, depending on the location of the lesion. It is confirmed by microscopical examination of a tissue sample. In Europe the five-year survival rate for colorectal cancer is less than 60% and in the developed world about a third of people who get the disease die from it.

An international team of scientists led by those at the Johns Hopkins University School of Medicine (Baltimore, MD, USA) included in a study 58 patients with stage I, II, or III CRC who underwent radical surgical resection at four Swedish hospitals from February 2, 2007, to May 8, 2013. Blood samples were collected at one month after the surgical procedure and every 3 to 6 months thereafter for circulating tumor DNA (ctDNA) analysis. Patients were followed up until metachronous metastases were detected, or for a median of 49 months. Data analysis was performed from March 1, 2009, to June 23, 2018.

While most of the patients did not have detectable levels of ctDNA in their blood after surgery, their search for known patient tumor mutations, using the Safe-SeqS assay, identified more than a dozen patients who were positive for ctDNA. The team found that disease recurrence and relapse occurred in all but three of the 13 early-stage CRC patients with post-surgical ctDNA, pointing to the potential benefit of ongoing testing for ctDNA after surgical tumor resection. On average, the ctDNA turned up in relapsing patients some three months before clinicians could see the recurrent disease by radiologic screening or clinical symptoms. The team did not see disease recurrence over an average of more than four years of follow up in the 45 remaining, ctDNA-free CRC patients.

Louise Olsson, MD, PhD, a corresponding author of the study, said, “Serial circulating tumor DNA levels during post-operative surveillance can be used as a triage test to stratify patients with resected colorectal cancer on the basis of their risk of recurrence.” The study was published on May 9, 2019, in the journal JAMA Oncology.

Related Links:
Johns Hopkins University School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.